Table 3.
The most toxicity outcomes
| CORRECT: regorafenib | |||||
| Any grade | Fatigue (285/500, 57%) | Hand–foot skin reaction (316/500, 64%) | Diarrhea (205/500, 42%) | Anorexia (168/500, 33%) | Hypertension (175/500, 35%) |
| Grade 3–5 toxicities | Hand–foot skin reaction (83/500, 17%) | Fatigue (51/500, 10%) | Diarrhea (36/500, 7%) | Hypertension (36/500, 7%) | Rash or desquamation (29/500, 6%) |
| CONCUR: regorafenib | |||||
| Any grade | Hand–foot skin reaction (100/136, 73%) | Hyperbilirubinaemia (50/136, 36%) | Alanine aminotransferase concentration increased (32/136, 23%) | Aspartate aminotransferase concentration increased (32/136, 23%) | Hypertension (31/136, 22.8%) |
| Grade 3–5 toxicities | Hand–foot skin reaction (100/136, 73%) | Hypertension (15/136, 11%) | Alanine aminotransferase concentration increased (9/136, 7%) | Hypophosphataemia (9/136, 7%) | Hyperbilirubinaemia (9/136, 6%) |
| FRESCO: fruquintinib | |||||
| Any grade | Hypertension (154/278, 55%) | Hand–foot skin reaction (137/278, 49%) | Proteinuria (117/278, 42%) | Dysphonia (100/278, 36%) | TSH level elevated (69/278, 25%) |
| Grade 3–5 toxicities | Hypertension (59/278, 21%) | Hand–foot skin reaction (30/278, 11%) | Proteinuria (9/278, 3%) | Diarrhea (8/278, 3%) | Platelet count decreased (7/278, 3%) |